Showcases Stock ranks Forex

Ionis Pharmaceuticals (IONS)
33.95  0.33 (0.98%) 03-24 16:00
Open: 33.43 Pre. Close: 33.62
High: 34.17 Low: 32.87
Volume: 812,233 Market Cap: 5,094(M)
Stock Technical Analysis
Target: Six months: 42.57
One year: 45.28
Support: Support1: 32.69
Support2: 27.20
Resistance: Resistance1: 36.45
Resistance2: 38.77
Pivot: 34.80
Moving Averages: MA(5): 34.82
MA(20): 35.13
MA(100): 38.98
MA(250): 39.94
MACD: MACD(12,26): -0.89
Signal(12,26,9): -0.95
%K %D: %K(14,3): 38.66
%D(3): 52.97
RSI: RSI(14): 36.56
52-Week: High: 48.82
Low: 31.46
Change(%): -4.9
Average Vol(K): 3-Month: 960
10-Days: 1086
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 34.187 - 34.356 34.356 - 34.526
Low: 32.48 - 32.652 32.652 - 32.826
Close: 33.668 - 33.946 33.946 - 34.227
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ IONS ] has closed above bottom band by 25.1%. Bollinger Bands are 17.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Stock chart
Stock News
Fri, 24 Mar 2023
Why Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report? - Zacks Investment Research

Fri, 24 Mar 2023
Why Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report? - Yahoo Finance

Fri, 24 Mar 2023
Ionis Pharmaceuticals Inc. (IONS) Shares Down Despite Recent ... - The News Heater

Thu, 23 Mar 2023
Biogen Stock Pops — But Ionis Stock Dips — On Mixed FDA View ... - Investor's Business Daily

Thu, 23 Mar 2023
Ionis Pharmaceuticals (IONS) Reports FDA's AdCom Voted ... -

Thu, 23 Mar 2023
Assenagon Asset Management S.A. Cuts Stake in Ionis ... - MarketBeat

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 142.95
Shares Float (M) 141.89
% Held by Insiders 0.56
% Held by Institutions 93.88
Shares Short (K) 8170
Shares Short Prior Month (K) 8180
Stock Financials
EPS -1.980
Book Value (p.s.) 4.030
Profit Margin -45.92
Operating Margin -69.49
Return on Assets (ttm) -9.9
Return on Equity (ttm) -40.1
Qtrly Rev. Growth -65.5
Gross Profit (p.s.) -1.804
Sales Per Share 4.109
EBITDA (p.s.) -2.738
Qtrly Earnings Growth
Operating Cash Flow (M) -274.37
Levered Free Cash Flow (M) -74.94
Stock Valuation
PE Ratio -17.15
PEG Ratio 0.15
Price to Book value 8.42
Price to Sales 8.26
Price to Cash Flow -17.69
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android